Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Investing.com -- Kestra Medical (TASE:BLWV) Technologies , Ltd. (NASDAQ:KMTS) reported a wide loss for its fourth quarter despite strong revenue growth, sending shares down 2.4% following the announcement.
The wearable medical device company posted revenue of $17.2 million for the fourth quarter ended April 30, 2025, representing a 71% increase YoY. However, the company reported a quarterly loss of -$2.21 per share. For the full fiscal year 2025, revenue reached $59.8 million, up 115% compared to fiscal 2024.
Kestra’s gross margin improved significantly to 44.3% in the fourth quarter, compared to 13.9% in the same period last year. The company attributed this improvement to volume leverage and a higher mix of in-network patients. Despite these gains, Kestra reported a GAAP net loss of $51.1 million for the quarter, more than double the $22.3 million loss in the prior year period.
"We capped an exciting year for Kestra with a very strong finish to our fiscal 2025. This quarter’s financial results reflect accelerating demand for our best-in-class cardiac recovery system," said Brian Webster, President and CEO.
The company reported that 3,903 prescriptions were written for its ASSURE® system during the quarter, a 43% increase YoY. Revenue growth was driven by increased share of wallet with existing customers and activation of new accounts.
Looking ahead, Kestra initiated fiscal year 2026 revenue guidance of $85 million, representing a 42% increase over fiscal 2025. The company ended the quarter with $237.6 million in cash and cash equivalents.
Operating expenses rose significantly to $55.8 million in the fourth quarter, including $22.3 million in share-based compensation expense and $3.8 million in professional services expenses related to the company’s IPO in March.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.